openPR Logo
Press release

Global Enzyme Inhibitor Market Set for Steady Growth at 3.9% CAGR Through 2032 | Pfizer Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Novartis AG

04-11-2025 11:29 AM CET | Health & Medicine

Press release from: DataM Intelligence 4 Market Research LLP

Enzyme Inhibitor Market

Enzyme Inhibitor Market

The latest report published by DataM Intelligence highlights the growth prospects of Enzyme Inhibitor market. The industry expansion is majorly driven by developments in technology across the globe.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/enzyme-inhibitor-market?ca

The Global Enzyme Inhibitor Market reached US$182.77 billion in 2023 and is expected to reach US$256.53 billion by 2032, growing at a CAGR of 3.9% during the forecast period 2024-2032.

An enzyme inhibitor is a molecule that binds to an enzyme and decreases its activity, thereby regulating biochemical reactions within the body. Enzyme inhibitors are widely used in medicine to treat various conditions, including hypertension, cancer, and infections, by targeting specific enzymes involved in disease pathways.

Competitive Evaluation:

Companies covered in this report are Pfizer Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Novartis AG, AbbVie Inc., Sanofi, AstraZeneca, Gilead Sciences, Inc., and Eli Lilly and Company.

The Enzyme Inhibitor Market analysis identifies a number of major market players. It enables companies to understand the strategies and partnerships used by other industry players to combat market competition. The comprehensive market report provides a fascinating microscopic look at the market. Corporations can detect the footprints of manufacturers by learning about demand, the global price of manufacturers, and the global benefit of manufacturing companies.

Key Development

In July 2024, the FDA approved ZORYVE (roflumilast) cream 0.15%, a PDE4 inhibitor from Arcutis Biotherapeutics, for treating mild to moderate atopic dermatitis in patients aged 6 and older. In June 2024, Bristol Myers Squibb received FDA accelerated approval for Augtyro (repotrectinib), a novel tyrosine kinase inhibitor, for treating NTRK-positive locally advanced or metastatic solid tumors.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/enzyme-inhibitor-market?ca

Enzyme Inhibitor Market Segments

The report covers the segmentation of the market into different segments based on various classifications such as applications, end users, product types, and others. The segmentation is divided into two sections, one for development and the other for different roles, needs, and behaviors.

By Enzyme Type: Angiotensin Converting Enzyme (ACE) Inhibitors, Cyclooxygenase (COX) Inhibitors, proton Pump Inhibitors, Protease Inhibitors, Beta-lactamase Inhibitors, HMG-CoA Reductase Inhibitors, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Phosphodiesterase (PDE) Inhibitors, Tyrosine Kinase Inhibitors,
Monoamine Oxidase (MAO) Inhibitors, Acetylcholinesterase (AChE) Inhibitors,
Poly (ADP-ribose) Polymerase (PARP) Inhibitors, Others
By Drug Class: Anti-Inflammatory Drugs, Anticancer, Antibiotics, Antiviral,
Antihypertensive, Antidiabetic, Gastrointestinal Drugs, Cardiovascular Drugs,
Neurological Drugs, Others
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies,
Others

Regional Assessment:

Regional analysis includes segmentation based on the geography that accentuates the recent and future demand for Enzyme Inhibitor market across North America, Europe, Asia-Pacific, Middle East & Africa, and South America. The study also focuses on the demand for each application segment over all the prominent regions.

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

In terms of geographical analysis, Enzyme Inhibitor Market report provides an in-depth view of:-

∎ Regional level break-up
∎ Leading growth rates
∎ Countries with the largest market share
∎ Market factors
∎ Latest developments
∎ Industry challenges
∎ Regulatory policies
∎ Player strategies

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/enzyme-inhibitor-market?ca

This report provides a 360-degree synopsis of the competitive scenario of the Enzyme Inhibitor industry. It has enormous awareness joined to the ongoing item and technical improvements in the business sector. It has a thorough analysis of the impact of the potential future development of these headways, a wide-ranging review of those extensions available for future growth.

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Browse More Reports: https://www.datamintelligence.com/research-report/enzyme-inhibitor-market

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Enzyme Inhibitor Market Set for Steady Growth at 3.9% CAGR Through 2032 | Pfizer Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Novartis AG here

News-ID: 3966959 • Views:

More Releases from DataM Intelligence 4 Market Research LLP

United States Automatic Packaging Robot Market 2025 | Industry Developments, Future Growth, Share & Industry Insights
United States Automatic Packaging Robot Market 2025 | Industry Developments, Fut …
Automatic Packaging Robot Market reached US$ 4.0 billion in 2023 and is projected to reach US$ 10.2 billion by 2031, growing at a CAGR of 12.4% during the forecast period 2024-2031. DataM Intelligence unveils its latest report on the "Automatic Packaging Robot Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and
Human Augmentation Market 2025 | Industry Developments, Future Growth, Share & Industry Insights
Human Augmentation Market 2025 | Industry Developments, Future Growth, Share & I …
The Human Augmentation Market reached US$ 252.6 billion in 2023 and is projected to reach US$ 780.7 billion by 2031, growing at a CAGR of 15.6% during the forecast period 2024-2031. DataM Intelligence unveils its latest report on the "Human Augmentation Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging
Learning Management System (LMS) Market 2025 | Industry Developments, Future Growth, Share & Industry Insights
Learning Management System (LMS) Market 2025 | Industry Developments, Future Gro …
Learning Management System (LMS) Market reached US$ 18.7 billion in 2023 and is projected to reach US$ 67.2 billion by 2031, growing at a CAGR of 17.7% during the forecast period 2024-2031. DataM Intelligence unveils its latest report on the "Learning Management System Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts,
Team Collaboration Tools Market 2025 | Industry Developments, Future Growth, Share & Industry Insights
Team Collaboration Tools Market 2025 | Industry Developments, Future Growth, Sha …
The Team Collaboration Tools Market reached US$ 23.3 billion in 2023 and is projected to reach US$ 62.8 billion by 2031, growing at a CAGR of 13.5% during the forecast period 2024-2031. DataM Intelligence unveils its latest report on the "Team Collaboration Tools Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts,

All 5 Releases


More Releases for Inhibitor

Advances in KRAS Inhibitor Development
The development of KRAS inhibitors has been a significant advancement in the field of oncology, offering new hope for patients with cancers driven by KRAS mutations. KRAS, a key gene involved in cell signaling, is frequently mutated in various cancers, including lung, colorectal, and pancreatic cancers. These mutations lead to uncontrolled cell growth and division, making KRAS a critical target for cancer therapy. Download Report: https://www.kuickresearch.com/report-kras-inhibitors-market-lumakras-sales-kras-drugs-market-kras-market-size Historically, KRAS was considered an undruggable target
Breakthroughs in KRAS Inhibitor Research
KRAS mutations have posed a significant challenge in oncology for decades, but recent breakthroughs in KRAS inhibitor research have sparked hope for new cancer therapies. KRAS is a key regulator of cell growth and survival, and its mutations are prevalent in various cancers, particularly lung, colorectal, and pancreatic cancers. Despite being one of the most sought-after targets, KRAS has been notoriously difficult to inhibit, earning the reputation of being "undruggable." Download
Checkpoint Inhibitor Refractory Cancer Market
Checkpoint Inhibitor Refractory Cancer Market Overview The global Checkpoint Inhibitor Refractory Cancer Market is poised for significant growth, anticipating a high CAGR during the forecast period from 2023 to 2030. Understanding Checkpoint Inhibitor Refractory Cancer Refractory cancer, which might not respond to treatments immediately or might develop resistance later, has driven significant growth and transformation in the global checkpoint inhibitor refractory cancer market. The interest of oncologists in the potential antitumor activity of
Fibroblast Growth Factor Receptor Inhibitor Market - Maximizing Therapeutic Pote …
Newark, New Castle, USA: The "Fibroblast Growth Factor Receptor Inhibitor Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Fibroblast Growth Factor Receptor Inhibitor Market: https://www.growthplusreports.com/report/fibroblast-growth-factor-receptor-inhibitor-market/8933 This latest report
Global Phosphodiesterase type 5 inhibitor (PDE5 inhibitor) Market Forecast 2023- …
The global Phosphodiesterase type 5 inhibitor (PDE5 inhibitor) market research report helps target customers understand the important driving factors and future opportunities of the industry. The report includes the dynamics of the macro environment such as the latest situation of the war between Russia and Ukraine, the update of monetary policy, and the impact of inflation on the market. Apart from this, the report studies key market developments such as
Avionic and electronic component corrosion inhibitor
Super CORR A was originally developed for the U.S. Air Force to comply with Mil-DTL-87177B (formerly Mil-L-87177A) specifications. A water displacing lubricant and corrosion protection compound that prevents avionic as well as electrical and electronic components from systems failures caused by corrosion. It is now the industry standard for electrical corrosion protection, for in service maintenance by both military and commercial aircraft major repair and overhaul (MRO) facilities worldwide. Super CORR